Navigation Links
Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Date:6/19/2008

ion for which mucus build up and clearance is a daily problem. Our bronchiectasis program follows closely behind our work in cystic fibrosis where a phase 3 clinical trial is expected to soon close recruitment.''

Pharmaxis is developing Bronchitol as a treatment to improve mucus clearance in the lungs of patients with cystic fibrosis, bronchiectasis and other acute and chronic pulmonary conditions. The U.S. FDA has granted Bronchitol fast track status and it is designated as an orphan drug in the U.S.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

CONTACT:

Alan Robertson

Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Released through:

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgro
'/>"/>

SOURCE Pharmaxis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Establishes Named Patient Program for Bronchitol
2. Pharmaxis Long-Term Safety Study of Bronchitol Completes
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
5. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
6. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
9. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
10. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
11. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Depomed, Inc. (NASDAQ: DEPO ) today announced ... Annual Healthcare Conference in New York City ... scheduled for 8:00 am EST (5:00 am PST) on Tuesday December ... be accessed via the Investor Relations page of the Depomed website ... archived for 30 days on the company,s website. ...
(Date:11/21/2014)... , Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... its previously announced underwritten public offering of $50,000,000 of ... shelf registration statement. The offering will consist of 49,751,244 ... of $1.005 per share.  Lexicon has also granted the ... additional shares of common stock.  All of the shares ...
(Date:11/18/2014)... , Nov. 18, 2014  Sanguine Biosciences – ... engagement and study recruitment – will use its ... to help Pfizer Inc. find and recruit people ... their family members to participate in voluntary research, ... DNA mutations and hopefully aid in informing the ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2
(Date:11/22/2014)... 2014 (HealthDay News) -- The widely used heart drug ... hospitalization among patients who have the heart rhythm disorder ... new study finds. Atrial fibrillation is a common ... a rise in risk for stroke among older Americans. ... to help treat irregular heartbeat, the authors of the ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 CRN International, ... veteran radio industry sales professional to its award-winning team. ... 30 years of leadership and sales experience to CRN. ... assume the title of Director of Strategy and Development, ... Robert O’Mara. , Heinemann will handle a wide range ...
(Date:11/21/2014)... Body Well Therapy, a leading provider of on-site ... massage gift cards and gift certificates for massage ... service areas including throughout Florida and the DC Metro area. ... spa at all to redeem your Spafinder massage gift card" ... may not be able to transport all of the bells ...
(Date:11/21/2014)... 20, 2014 (HealthDay News) -- The cost of diabetes ... in recent years, climbing to more than $322 billion ... in cost were seen with prediabetes care, which have ... 82 percent, the researchers added. In 2012, excess ... more than $1,000 for every American. That total includes ...
(Date:11/21/2014)... 2014 (HealthDay News) -- Scientists say they,ve mapped the genome ... a British man,s brain, in hopes it might help others ... in the journal Genome Biology , the tapeworm was ... Chinese ethnicity. "This infection is so rare worldwide and ... diagnosed ... until the worm was pulled out from the ...
Breaking Medicine News(10 mins):Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 3Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2
... Interfere with Prescribed TherapiesSACRAMENTO, Calif., May 11 The ... a national network of over 250 physicians with the ... approved medical treatments and therapies, today cited a recent ... a large number of physicians believe insurance companies are ...
... announced today that for the quarter ended March 31, 2009, it ... share, on revenues of $5.2 million compared to a net loss ... $5.2 million in the previous year. The loss from continuing operations ... to income of $3.2 million for the same period in 2008. ...
... 11, 2009; 3 pm Central Daylight Time) Many ... into the office complaining of chest pain, undergoes a stress ... results suggest coronary artery disease, a condition in which plaque ... for an angiogram to look at the coronary arteries and ...
... available in French . , Montreal, May ... not have been dealt an equal hand. The latest study ... McGill University Health Centre and McGill University, shows that women ... the production of estrogen by females could have a beneficial ...
... Trust Incorporated (NYSE: HR ) today announced results ... from operations ("FFO") per diluted common share for the three ... for the three months ended March 31, 2008. FFO ... three months ended March 31, 2009, before the recognition of ...
... (NYSE: HR ) today announced its common stock ... This dividend, in the amount of $0.385 per share, is ... May 22, 2009. The total dividend of $22.8 million ... in accordance with GAAP. The Company,s cash flow statement ...
Cached Medicine News:Health News:Alliance for Patient Access Wants Health Care Code of Conduct 2Health News:Westaim announces 2009 first quarter results 2Health News:Westaim announces 2009 first quarter results 3Health News:Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events 2Health News:Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events 3Health News:Equality of the sexes? Not always when it comes to biology 2Health News:Healthcare Realty Trust Announces First Quarter Results 2Health News:Healthcare Realty Trust Announces First Quarter Results 3Health News:Healthcare Realty Trust Announces First Quarter Results 4Health News:Healthcare Realty Trust Announces First Quarter Results 5Health News:Healthcare Realty Trust Announces First Quarter Results 6Health News:Healthcare Realty Trust Announces First Quarter Results 7Health News:Healthcare Realty Trust Announces First Quarter Results 8Health News:Healthcare Realty Trust Announces First Quarter Results 9Health News:Healthcare Realty Trust Announces First Quarter Dividend 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 3Health News:Healthcare Realty Trust Announces First Quarter Dividend 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: